Background. Human adenovirus (HAdV) infections are increasingly frequent complications of allogeneic stem-cell transplantation (SCT), especially in children. Only a few data on the correlation between immune recovery and the course of HAdV infection are available, and data on HAdV-specific responses are lacking.
In recent years, human adenovirus (HAdV) infections have been observed with increasing frequency after allogeneic stem-cell transplantation (SCT), especially in young children, and result in high mortality when the virus disseminates [1] [2] [3] [4] [5] [6] [7] [8] . Currently, 51 serotypes of HAdV have been identified, classified into 6 species (A-F) [9, 10] . Species A, B, and C serotypes are most frequently isolated from immunocompromised pediatric hosts and are the major cause of HAdV-related disease [1, 9, 11] . Unfortunately, HAdV infections are usually not recognized until a late stage of disease is reached, because of nonspecific clinical symptoms of infection in an immunocompromised host. Virologicalculture techniques for diagnosis are time-consuming and moderately sensitive for detection of progression to viremia [12, 13] . By use of real-time quantitative polymerase chain reaction (RQ-PCR) techniques, patients can receive diagnoses at an early stage of viremia, and the course of infection can be monitored by quantification of the HAdV DNA load in plasma [14] [15] [16] [17] .
Immunological recovery after SCT is of great importance for clearance of viral infections, as has been shown for other viral reactivations, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations [18] [19] [20] [21] [22] [23] [24] . So far, only a few data on the correlation between lymphocyte recovery and HAdV infection are available [25] , and no data on HAdVspecific cellular and humoral immune reconstitution in relation to the course of HAdV infection in SCT recipients have been published. Better understanding of the role that immune recovery plays in adenovirus infections might be relevant for improvement of therapeutic options, because treatment with ribavirin or cidofovir is not unequivocally effective [26] [27] [28] [29] [30] [31] [32] .
We conducted a prospective study in which all pediatric allogeneic SCT recipients who received transplantations between 2001 and 2003 were monitored weekly for HAdV infection by culture of feces, throatswab, and urine samples, as well as by RQ-PCR analysis of plasma samples. Lymphocyte recovery and HAdV-specific T and B cell responses were investigated in HAdV-infected patients at the onset and during the course of the infection.
PATIENTS AND METHODS

Patient cohort.
In 2001 and 2002, 53 pediatric patients received an allogeneic SCT in the pediatric bone marrow-transplant unit of the Leiden University Medical Center. The present study has been approved by the local institutional review board, and all patients included in the study provided informed consent. Five patients died within 2 months after SCT as a result of transplantrelated complications or relapse. Characteristics, donor types, and graft manipulations of the 48 remaining patients are summarized in table 1. Pretreatment of the graft recipient was performed in accordance with disease-specific protocols of the relevant working parties of the European Group for Blood and Marrow Transplantation. Rabbit-antithymocyte globulin (ATG) (IMTIX; 10 mg/kg for 4 days) or Campath-1H (1 mg/kg for 5 days) was given to all HLA-nonidentical SCT recipients shortly before the transplantation date. Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporin A (CsA; trough level, 100-200 mg/ L). All patients were kept in protective isolation for at least 4 weeks after SCT and received total gut decontamination. Neither systemic antibacterial nor antiviral prophylaxis was given; preemptive treatment was administered for proven (i.e., RQ-PCRbased) CMV (ganciclovir) and EBV (administration of rituximab for depletion of B cells, to prevent posttransplant lymphoproliferative disease) reactivation. For HAdV viremia, ribavirin (60 mg/kg/day; starting dose, 30 mg/kg) or cidofovir (5 mg/kg/week) was given [32] . Intravenous immunoglobulin (IVIG) substitution was given to patients with grafts from unrelated donors for 3-6 months after SCT.
Virological monitoring. Patients were screened for 6 months after SCT; samples were obtained weekly during the first 8-12 weeks and every 2-4 weeks thereafter. In this cohort, retransplantation ( ) was considered to be an endpoint for follown p 3 up. Feces, urine, and throat-swab samples were inoculated on human A549 cells and scored for cytopathological effect (CPE). Plasma samples were tested for the presence of HAdV DNA by RQ-PCR. DNA was extracted from plasma by standard procedures, and 10 mL of DNA-containing extract was amplified by RQ-PCR by use of oligonucleotide primers described elsewhere [33] . The amplification protocol was 15 min at 95ЊC, followed by 50 cycles of 95ЊC, 55ЊC, and 72ЊC (each 30 s). To detect these amplified products, a molecular beacon (GAGCC-CACCCTTCTTTATGT) with a 5 FAM label and a 3 dabcyl label was applied (Biolego) by use of an iCycler IQ system (Biorad laboratories). Sensitivity of the assay was 50-250 copies/mL [34] . Quantitated HAdV5 stock was a gift from M. Havenga (Crucell, Leiden, The Netherlands).
HAdV infection was defined as у2 consecutive positive viral cultures. Likewise, HAdV viremia was defined as the presence of 11000 copies/mL HAdV DNA in у2 consecutive plasma samples. Serotype analysis of HAdV isolates was performed by virus neutralization by use of a panel of type-specific antisera (RIVM).
Viruses. HAdV serotypes 1, 2, 5, and 11 (RIVM) were grown on human Hep2 cells. Virus was released from the cells by 2 freeze-thaw cycles and was purified by CsCl density-gradient centrifugation. Virus stocks were titrated by use of the plaque assay on 293 cells. Purified HAdV serotypes 6 and 31 were a gift from M. Havenga.
For the antibody neutralization assay, crude lysates of HAdVinfected cells (Hep2 or A549 cells) were generated as described above. The TCID 50 of each lysate was determined by diluting the lysate 10-fold, from 10 0 to 10
12
, followed by addition of Hep2 or A549 cells. After 7 days, the TCID 50 was calculated as the dilution at which 50% of 10 wells showed CPE.
Immunological reconstitution. Leukocyte and lymphocyte counts were determined every 1-3 days during the first 2 months after SCT. Subset analysis of peripheral blood mononuclear cells (PBMCs) (i.e., CD4 + T, CD8 + T, NK, and B cells) was performed every 4-8 weeks, when sufficient lymphocytes were present (usually from 4-8 weeks after SCT onward), by flow cytometric analysis.
HAdV-specific antibodies. To determine titers of neutralizing antibodies (NAbs), serum samples were heat inactivated for 30 min at 56ЊC and diluted 2-fold, from 1:4 to 1:2048, in a 96-well plate in duplicate. HAdV lysate was diluted to 100ϫ TCID 50 , added to each well, and incubated for 1 h at 37ЊC. Hep2 or A549 cells were added, and wells were scored for CPE after 7 days of culture. The neutralizing titer was the highest serum dilution at which CPE was no longer observed. Increases in titers (14-fold increase) of NAbs against the serotype with which the patient was infected that occurred while titers of NAbs against other serotypes remained stable were considered to be specific responses.
HAdV-specific proliferation. Autologous irradiated stimulator PBMCs (30 Gray) were infected (MOI, 100) with the purified HAdV serotype with which the patient was infected. For uninfected patients, PBMCs were infected with the common serotype HAdV5, because HAdV-specific T cells are usually cross-reactive [35] . Infection was performed in RPMI/0.5% bovine serum albumin (Sigma-Aldrich), at 10 7 cells/mL, and, after 1 h, the PBMC concentration was adjusted to 10 6 cells/ mL by use of RPMI/10% human AB serum. 13 was considered to be a specific response. As a control, PBMCs (4 ϫ 10 4 PBMCs/well) were stimulated for 4 days in a 96-well flatbottom plate, with a-CD3 antibodies (Janssen-Cilag BV), a-CD3 plus interleukin-2 (50 IU/mL; Chiron), or 5 mg/mL phytohemagglutinin (Murex).
HAdV-specific production of cytokines. For interferon (IFN)-g ELISPOT, PBMCs ( PBMCs/well) in RPMI/10% 5 2 ϫ 10 human antibody serum either were stimulated (MOI, 10) with the HAdV serotype with which the patient was infected, in a 96-well round-bottom plate, or were not stimulated (control). After 4 days, IFN-g ELISPOT was performed in accordance with the manufacturer's instructions (Mabtech) [36] . A specific response was defined as 125 specific spots ( ). spots Ϫ spots
HAdV control
For intracellular cytokine staining, cells were incubated with brefeldin A (5 mg/mL; Sigma-Aldrich) for 5 h at day 5 and were stained for IFN-g or tumor necrosis factor (TNF)-a, as described elsewhere [37] . The antibodies used were aCD3-peridinin chlorophyll protein-Cy5.5, aCD4-fluorescein isothiocyanate, aIFNg-phycoerythrin (PE) or aTNF-a-PE (Becton Dickinson), and aCD8-allophycocyanin (Beckman Coulter). Cells were analyzed by use of a FACSCalibur flow cytometer with CellQuest software (Becton Dickinson).
Statistical analysis. Transplant-related variables and immune reconstitution were evaluated in relation to HAdV infection and viremia, by univariate analyses in binary logistic regression models, with SPSS software (version 10; SPSS). Multivariate analysis was not performed, because of small numbers of patients.
RESULTS
Incidence of HAdV infection and viremia.
HAdV infection was present in 21 (44%) of 48 patients. Detailed information on the 21 infected patients is given in table 2. Three of the 21 patients were lost to follow-up (patients 1-3 in table 2), because of retransplantation or transplant-related mortality. In 6 (33%; ), and, at P p .025 day 30, patients surviving HAdV viremia had higher lymphocyte counts than did patients who died of HAdV viremia ( ). P p .067 patients 16-21) of the remaining 18 patients, the infection progressed to viremia, as defined by the presence of HAdV DNA in plasma. Of these patients, 3 survived the infection, 2 died of HAdV (1 after a second SCT), and 1 died of HAdV as a probable cofactor in combination with GvHD.
The Kaplan-Meier curve for infection, in correlation with the type of donor, shows that patients with grafts from matched family donors and from mismatched family donors (MMFDs), as well as patients with grafts from matched unrelated donors (MUDs), were infected with HAdV at similar frequencies (figure 1) . However, only in patients with grafts from MUDs did the infection progress to viremia (data not shown).
The onset of infection in patients whose viremia status remained negative by PCR (median [range], 31 days after SCT) was not significantly different from that in patients with HAdV viremia (median [range], 22 days after SCT) ( ) (table 2) . Plasma samples were first found to be P p .129 positive by PCR at a median (range) of 26 (0-49) days. PCR positivity followed 1-3 weeks after the first positive culture in 4 patients and preceded the first positive culture by 1-2 weeks in 2 patients. Duration of the infection was, in some cases, prolonged, both in patients with and in those without HAdV viremia, indicating that sustained infection can occur without progression to viremia (table 2) .
At the time of the first detection of HAdV DNA in plasma, clinical symptoms that could exclusively be attributed to HAdV were not observed; in patients who died of infection, severe symptoms, such as liver failure, were evident only at the end stage of the disease. All 21 infected patients were found to have HAdV-positive feces samples by culture; in 11 patients, no sample from other sites was found to be positive by culture. Four of the 5 patients who had samples from multiple sites, including urine, found to be positive by culture also had HAdV viremia, as defined by the presence of HAdV DNA in plasma (table 2) .
Risk factors for HAdV infection and viremia. Risk factors for HAdV infection were HLA-mismatched donors (у1 mismatch;
), serotherapy with ATG or Campath in vivo P p .017 ( ), and melphalan in the conditioning regimen (P P p .026 p .018). To determine the risk factors for viremia (PCR positivity), patients with HAdV viremia were compared with HAdV-infected patients without HAdV viremia. A graft from 
had grade IV acute graft-versus-host disease (GvHD) and Epstein-Barr virus (EBV) infection, and patient 21 had grade II acute GvHD and cytomegalovirus infection (data not shown). B, Absolute CD4
+ and CD8 + T cell counts, as well as counts of NK and B cells per microliter of blood, at several time points before and after SCT. C, Titers of HAdV-specific NAbs against the serotype with which the patient was infected. Treatment with a-CD20 antibodies (rituximab) for EBV reactivation is indicated (᭤). The HAdV DNA loads of these 3 patients, for evaluation of treatment with ribavirin, have been described elsewhere [32] .
a MUD was a risk factor for viremia ( ), as was female P p .005 sex of the recipient (
). All other variables tested in P p .016 univariate analyses-such as ex vivo manipulation of the graft (by either T cell depletion or CD34 + enrichment), underlying disease, use of CsA, occurrence of GvHD, and age of the recipient-were not significantly correlated with HAdV infection or viremia.
Immune reconstitution and course of HAdV infection. Because delayed recovery of the immune system might be of importance for the occurrence and progression of HAdV infection, absolute leukocyte and lymphocyte counts were compared between uninfected patients, HAdV-infected patients, and patients with HAdV viremia. The time to leukocyte reconstitution (set at leukocytes/L) was identical in all 9 1 ϫ 10 groups (data not shown), whereas lymphocyte reconstitution (set at lymphocytes/L) was significantly delayed in 9 0.2 ϫ 10 patients who developed viremia ( ) ( figure 2A ). P p .027 Furthermore, absolute lymphocyte counts were determined at the onset of infection and during the first 30 days thereafter. Patients with HAdV viremia had lower lymphocyte counts (geometrical mean, 62 lymphocytes/mL) at the onset of infection than did those without HAdV viremia (geometrical mean, 310 lymphocytes/mL) ( ) ( figure 2B ). Furthermore, in P p .025 the 6 patients with HAdV viremia, an increase in lymphocyte counts during the next 30 days correlated with clearance of the infection and survival of the host (geometrical mean, 926 lymphocytes/mL in patients surviving HAdV viremia vs. 28 lymphocytes/mL in patients who died of HAdV viremia; P p .067). Patients who died of HAdV viremia had continuously increasing HAdV DNA loads in plasma without lymphocyte recovery (figure 3A) [32] , whereas, in patients surviving HAdV viremia, lymphocyte recovery coincided with a decrease in HAdV DNA load ( figure 4A ). All lymphocyte subsets (e.g., T, B, and NK cells) were recovered in patients surviving HAdV viremia, whereas only few lymphocytes were recovered in patients who died of HAdV viremia (figures 4B and 3B, respectively). Viral infections other than HAdV occurred in patients from both groups and were successfully treated with ganciclovir and rituximab. Of the 3 patients who survived HAdV viremia, 1 received no antiviral medication targeted at HAdV, 1 received + and CD8 + T cell counts, as well as counts of NK and B cells per microliter of blood, at several time points before and after SCT. C, Titers of HAdV-specific NAbs against the serotype with which the patient was infected. The specific NAb response (14-fold increase in titer; see Patients and Methods) is indicated by an arrow. Treatment with a-CD20 antibodies (rituximab) for EBV reactivation is indicated (᭤). D, HAdV-specific T cell responses, in relation to the time after SCT. Peripheral blood mononuclear cells from donors and patients were stimulated with the HAdV serotype with which the patient was infected and were tested for proliferation (shown as stimulation index [SI]; Ⅵ) and production of interferon (IFN)-g, by ELISPOT (bars are HAdVspecific spots after subtraction of background spots). The first detection of HAdV-specific T cell responses is indicated by an arrow. a short course of cidofovir, and 1 received a short course of ribavirin. However, clearance of HAdV viremia coincided with increasing lymphocyte counts in all 3 patients. Moreover, inefficacy of treatment with ribavirin was documented in the 3 patients who died of HAdV viremia without lymphocyte recovery [32] .
HAdV-specific immune recovery. In patients who died of HAdV viremia, serotype-specific NAbs were present in serum before infection, in some cases even at high titers ( figure 3C,  patients 20 and 21) . Nevertheless, infection, as well as progression to viremia, occurred in these patients. During the infection, titers gradually declined to low levels.
In patients with HAdV viremia who cleared the infection, humoral immune responses were observed-titers of serotypespecific NAbs increased 8-16-fold (figure 4C)-whereas titers of NAbs against other serotypes remained unchanged (data not shown). Responses were observed 1-9 months after clearance of HAdV from the plasma. Patient 18 received treatment with rituximab because of EBV reactivation, which might explain the delayed humoral response to HAdV. The early increases in titers of NAbs shortly after SCT in patients 16 and 17 were most likely due to administration of IVIG, since titers of NAbs against other serotypes increased simultaneously (data not shown).
Since PBMCs from patients who died of HAdV viremia were Figure 5 . Human adenovirus (HAdV)-specific T cell responses detected in most HAdV-infected patients without viremia and in some uninfected patients, at 6 months after stem-cell transplantation (SCT). HAdVinfected patients without viremia were tested for HAdV-specific responses at 3 months ( ) and 6 months ( ) after SCT; some uninfected n p 7 n p 8 patients (
at both time points) were also tested. The no. of HAdVn p 6 specific interferon (IFN)-g-producing cells, determined by ELISPOT, is shown (a response was defined as 125 spots). At 3 months, 3 (43%) of 7 HAdV-infected patients had HAdV-specific responses against the infecting HAdV serotype; 2 (33%) of 6 uninfected patients had specific responses against the common serotype HAdV5. At 6 months, 6 (75%) of 8 HAdV-infected patients had developed an HAdV-specific response, whereas 33% of uninfected patients had developed an HAdV-specific response. ⅜, HAdV-infected patients in whom infection was cleared from the feces before that time point; ⅷ, HAdV-infected patients in which feces was still HAdV positive at that time point; Ⅺ, uninfected patients. not available, because of poor recovery of lymphocytes, we were unable to test for HAdV-specific T cells in these patients. In patients surviving HAdV viremia, HAdV-specific responses were observed ∼5-6 weeks after clearance of viremia in 2 patients (patients 16 and 18) and 6 months after clearance of viremia in 1 patient (patient 17) ( figure 4D ). Accordingly, recovery of T cells was fast in patients 16 and 18, whereas recovery of T cells was delayed in patient 17 (figure 4B). The latter observation was reflected by severely impaired responses to a-CD3 stimulation in this patient before detection of HAdVspecific T cells (data not shown).
HAdV-specific T-cell responses were also investigated, at 3 and 6 months after SCT, in HAdV-infected patients without HAdV viremia and in some patients without HAdV infection (figure 5). At 3 months, responses to the infecting serotype were observed in 3 (43%) of 7 HAdV-infected patients, and 2 (33%) of 6 uninfected patients responded to HAdV5. At 6 months, the percentage of HAdV-infected patients with specific T cell responses increased to 75% (6 of 8 patients), whereas the percentage of uninfected patients with specific T cell responses remained at 33% (figure 5).
Intracellular cytokine staining after in vitro stimulation of PBMCs with HAdV revealed that most IFN-g-and TNF-aproducing cells were CD4 + T cells, both in donors and in patients (figure 6 and data not shown). These data suggest that the HAdV-specific T cells detected after clearance of infection are CD4 + T cells with a Th1-like phenotype.
DISCUSSION
In the present prospective study, 48 pediatric SCT recipients were monitored for the occurrence of HAdV infection and viremia in relation to HAdV-specific immune reconstitution. The value of detection of HAdV DNA in plasma, for the diagnosis and management of viral infections-such as EBV and CMV and, more recently, HAdV-has been well documented [15-17, 33, 38-40] . Quantification of the HAdV DNA load is essential because only persistent and increasing loads have been shown to correlate with progressive disease and, eventually, death [12, 13] . In the present study, infection occurred in 44% of patients, of whom 33% developed viremia, as documented by the presence of HAdV DNA in plasma. The risk factors identified in the present study-HLA-mismatched transplants and immunosuppression by use of ATG or Campath in vivo-are likely to have an impact on lymphocyte recovery [5, 6, 25, 41] . A low lymphocyte count at the time of the first virus isolation was a strong predictor of HAdV viremia. Furthermore, increasing lymphocyte counts during the first weeks of HAdV viremia were correlated with survival of the host. In patients who died of HAdV viremia, the lack of increase in lymphocyte counts could be due to a variety of factors, such as the occurrence and treatment of GvHD or retransplantation. This strong correlation between lymphocyte recovery and clearance of HAdV viremia confirms and extends the findings of a previous study [25] and is in accordance with results obtained with respect to CMV infection [23, 24, 42] . The present study is, to our knowledge, the first in which HAdV-specific immunity was investigated longitudinally in SCT recipients with documented infection. Serotype-specific humoral immune responses were detected in patients recovering from HAdV viremia several weeks to months after clearance of viremia. In comparison, peak titers of HAdV-specific antibodies in healthy individuals were observed 2-4 weeks after administration of adenoviral vector for gene-therapy purposes [43] . This difference in kinetics is probably due to the slowly recovering immune system in allogeneic SCT recipients. Interestingly, the presence of preexisting, high titers of HAdV-specific NAbs in serum from 2 of 6 patients did not prevent progression to viremia. Viremia did not occur in 9 HAdV-infected patients, despite the fact that 5 patients had only low titers (р32) of NAbs and 3 patients had intermediate titers of NAbs at the time of infection. Together, these results suggest that the role that preexisting NAbs (as measured in vitro) play in protection against progression to viremia may be limited. As the number of patients in the present study was small, to confirm these findings, more patients should be evaluated.
In patients who cleared HAdV viremia, predominantly HAdVspecific CD4 + T cells producing IFN-g were detected weeks to months after clearance of viremia. In healthy blood-bank donors, HAdV-specific CD4 + T cells producing IFN-g on HAdV stimulation in vitro have also been detected [35, 44] . In individual patients, the increase in total lymphocyte counts coincided with a decrease of HAdV DNA in plasma. As this result suggests a causal relationship, the question of why specific humoral or cellular responses were detected only at later time points remains. At this stage, we can only speculate about the reasons for this observation. The decrease in HAdV DNA load strongly suggests that a specific immune response has been initiated at the site of infection, but it might be that responses are undetectable in the circulation because the frequency of specific cells is below the limit of detection. In CMV and varicella zoster virus infections, specific CD4 + cells were also observed only after clearance of viremia in patients with symptomatic disease [45] (R. van Lier, personal communication), possibly reflecting the redistribution characteristics of CD4 + T cells after viral infection. In other viral infections, such as EBV, the presence of specific CD8 + cells at the time of clearance of viremia has recently been demonstrated by use of major histocompatibility complex-antigen tetramers, making detection independent of in vitro functionality [46, 47] . Defining HAdVspecific immunodominant epitopes, as has been described by Olive et al. [48] , may be instrumental in the detection of HAdVspecific T cells at earlier time points by use of tetramer technology. Another possibility is that the initial control of infection is established by other (innate) immune mechanisms-for instance, NK cells-whereas the adaptive immune response is initiated at a later time point. Further research is needed to address these questions.
Weekly RQ-PCR-based screening of plasma for HAdV during the first months after allogeneic SCT, especially in recipients of grafts from MMFDs or MUDs, identifies high-risk patients at an early stage of viremia. If viremia is accompanied by an increase in lymphocyte counts, the viral infection will most likely be controlled. When lymphocyte counts remain low, alternative measures should be taken. Since the antiviral effect of ribavirin appears to be limited and since cidofovir has not been not proven to be unequivocally effective [26, 27, [29] [30] [31] [32] , other interventions aimed at improving immune reconstitution should be considered. Tapering of the immunosuppression after SCT, to improve the outcome of the infection, has been suggested [25] . However, this strategy bears a high risk of concurrent, severe GvHD, especially in a recipient of a non-HLA-identical transplantation. Adoptive immunotherapy with HAdV-specific T cells, as has been performed for EBV and CMV [49] [50] [51] , or infusion of donor cells that have been depleted of alloreactive T cells [52, 53] might, in the near future, be options for treatment of immunocompromised graft recipients at early stages of HAdV viremia.
